Major Shareholder Tang Capital Commits 9% Stake to Aurinia Merger
KZR has more than doubled off its 52-week low of $3.533 on elevated volume (2.0× avg).
Summary
Tang Capital Management and Kevin Tang, holding 9.0% of Kezar Life Sciences, have entered into a Tender and Support Agreement, committing their shares to the acquisition by Aurinia Pharmaceuticals and rescinding their prior acquisition proposal.
Key Events · Ownership and Investor Activity · KZR
-
Major Shareholder Support for Merger
Tang Capital Management, LLC and Kevin Tang, who collectively beneficially own 664,314 shares representing 9.0% of Kezar Life Sciences' outstanding common stock, have entered into a Tender and Support Agreement.
-
Commitment to Tender Shares
The Reporting Persons have agreed to tender all of their shares in connection with the Agreement and Plan of Merger with Aurinia Pharmaceuticals, Inc., which was announced on March 30, 2026.
-
Prior Acquisition Proposal Rescinded
Concentra Biosciences, LLC, an entity controlled by Tang Capital, has formally rescinded its previous acquisition proposal to acquire 100% of Kezar Life Sciences' equity, originally sent on October 8, 2024.
Analysis · KZR · Life Sciences
This Schedule 13D/A provides a crucial update following the announcement of Kezar Life Sciences' acquisition by Aurinia Pharmaceuticals on March 30, 2026. Tang Capital Management and Kevin Tang, a significant 9.0% shareholder, have formally agreed to tender their shares in support of the merger. This commitment from a major investor significantly increases the certainty of the acquisition's completion. Furthermore, Concentra Biosciences, LLC, controlled by Tang Capital, has rescinded its previous acquisition proposal, removing any potential competing bids and streamlining the merger process. The stock is currently trading near its 52-week high, reflecting the market's reaction to the merger news.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KZR was trading at $7.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.2M. The 52-week trading range was $3.53 to $7.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.